Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 339-345

  Gnant, M ^a   Filipits, M ^b   Greil, R ^c   Stoeger, H ^d   Rudas, M ^a   Bago Horvath, Z ^a   Mlineritsch, B ^c   Kwasny, W ^e   Knauer, M ^f   Singer, C ^g   Jakesz, R ^a   Dubsky, P ^a   Fitzal, F ^a   Bartsch, R ^a   Steger, G ^a   Balic, M ^d   Ressler, S ^c   Cowens, J W ^h   Storhoff, J ^h   Ferree, S ^h   Schaper, C ⁱ   Liu, S ^j   Fesl, C ^k   Nielsen, T O ^j   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

^e State Hospital Wiener Neustadt   (Austria)

^f Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

^g UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^h NANOSTRING TECHNOLOGIES   (United States)

ⁱ Myraqa   (United States)

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

^k Austrian Breast and Colorectal Cancer Study Group   (Austria)

more..

Author keywords

Clinical prognostic factors; Early breast cancer; Intrinsic subtypes; Metastasis prediction; Prognosis; Risk of Recurrence (ROR)

Indexed keywords

ANASTROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; NITRILE; TRANSCRIPTOME; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BASAL LIKE BREAST CANCER SUBTYPE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; DISTANT METASTASIS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION ASSAY; HER2 ENRICHED BREAST CANCER SUBTYPE; HUMAN; HUMAN TISSUE; LUMINAL A BREAST CANCER SUBTYPE; LUMINAL B BREAST CANCER SUBTYPE; MAJOR CLINICAL STUDY; PAM50 RISK OF RECURRENCE SCORE; POSTMENOPAUSE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RNA ANALYSIS; SCORING SYSTEM; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; POSTMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK; RISK ASSESSMENT; TAMOXIFEN; TRANSCRIPTOME; TREATMENT OUTCOME; TRIAZOLES;

EID: 84893424611     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt494     Document Type: Article

References (17)

1. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Gnant M, Steger GG. Fighting overtreatment in adjuvant breast cancer therapy. Lancet 2009; 374: 2029-2030.
4. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care 2011; 6: 136-141.
5. Blomer JU, Rezai M et al. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. J Med Econ 2013; 16: 30-40.
6. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011; 22: 1736-1747.
7. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
8. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.
9. Dowsett M, Sestak I, Lopez-Knowles E et al. on behalf of the ATAC and LATTE Trialists Group. Comparison of PAM50 risk of recurrence (ROR) score with oncotype DX and IHC4 for predicting risk of recurrence and distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783-2790.
10. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65.
11. Jonat W, Gnant M, Boccard F Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006; 7: 991-996.
12. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009; 101: 1446-1452.
13. Filipits M, Rudas M, Jakesz R et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012-6020.
14. Dubsky P, Filipits M, Jakesz R et al. Endopredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 2012; 0: 1-8.
15. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691, 2009.
16. Jakesz R, Jonat W, Gnant M et al. ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
17. Sgroi DC, Sestak I, Cuzick J et al. Comparative performance of Breast Cancer Index (BCI) versus oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: a TransATAC study. Abstract-San Antonio Breast Cancer Symposium 2012.